DADC
KERX

D.A. Davidson & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

D.A. Davidson & Co’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,700
Closed -$19K – 2271
2017
Q2 		$19K Hold
2,700
– – ﹤0.01% 1845
2017
Q1 		$16K Sell
2,700
-800
-23% -$4.38K ﹤0.01% 1901
2016
Q4 		$20K Hold
3,500
– – ﹤0.01% 1932
2016
Q3 		$18K Hold
3,500
– – ﹤0.01% 1892
2016
Q2 		$23K Sell
3,500
-3,000
-46% -$16.8K ﹤0.01% 1726
2016
Q1 		$30K Buy
6,500
+2,200
+51% +$8.78K ﹤0.01% 1579
2015
Q4 		$21K Hold
4,300
– – ﹤0.01% 1693
2015
Q3 		$15K Sell
4,300
-886
-17% -$5.93K ﹤0.01% 1760
2015
Q2 		$51K Buy
5,186
+1,037
+25% +$11.1K ﹤0.01% 1429
2015
Q1 		$52K Buy
4,149
+200
+5% +$2.57K ﹤0.01% 1420
2014
Q4 		$55K Buy
3,949
+1,500
+61% +$23.2K ﹤0.01% 1399
2014
Q3 		$33K Buy
2,449
+449
+22% +$6.87K ﹤0.01% 1551
2014
Q2 		$30K Hold
2,000
– – ﹤0.01% 1554
2014
Q1 		$34K Hold
2,000
– – ﹤0.01% 1519
2013
Q4 		$25K Hold
2,000
– – ﹤0.01% 1495
2013
Q3 		$20K Hold
2,000
– – ﹤0.01% 1345
2013
Q2 		$14K Buy
+2,000
New +$15.6K ﹤0.01% 1385

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

D.A. Davidson & Co's KERX Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2017, closing a stake of 2,700 shares — an estimated $19K sold.

D.A. Davidson & Co first reported a position in KERX in Q2 2013 and held it in 17 quarters. The position peaked at $55K in Q4 2014. 132 funds tracked by Wall St. Rank hold KERX as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 2,700 Keryx Biopharmaceuticals Inc shares in Q3 2017, an estimated $19K.
  • D.A. Davidson & Co first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 17 quarters.
  • D.A. Davidson & Co's Keryx Biopharmaceuticals Inc position peaked at $55K in Q4 2014.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.